Oncologists' experiences with drug shortages

Kenneth L. Kehl, Stacy W. Gray, Benjamin Kim, Katherine L. Kahn, David Haggstrom, Maryse Roudier, Nancy L. Keating

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: There have been numerous reports of shortages of injectable drugs for cancer in the last decade. We assessed physician experiences with drug shortages in a population-based cohort of medical oncologists caring for patients with lung or colorectal cancer. Methods: Wesurveyed medical oncologists caring for patients with lung or colorectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium from 2012 to 2013 (participation rate, 53%). Oncologists reported experiences with shortages of leucovorin, fluorouracil, dexamethasone, cyanocobalamin, paclitaxel, cisplatin, and etoposide in the prior year and whether they had used a less-effective alternative because of a shortage. We used multivariable logistic regression to assess for associationsbetweenphysician or practice characteristics and encountering shortages. Results: Among 330 respondents, 74% reported experiences with a shortage of at least one drug in our survey, and 28% reported using a less-effective alternative because of a shortage. Although physician demographic characteristics did not predict reports of drug shortages, practice characteristics did. Veterans Affairs (VA) oncologists were less likely to report experiencing any shortage than oncologists in single-specialty group practice (odds ratio [OR], 0.4; 95% CI, 0.2 to 0.9). The reported use of a less effective alternative to any drug was also less common among VA oncologists (OR, 0.3; 95% CI, 0.1 to 0.9) and oncologists affiliated with health maintenance organizations (OR, 0.4; 95% CI, 0.2 to 0.9) compared with physicians in single-specialty groups. Conclusion: Most oncologists encountered drug shortages in the year before our survey, but experiences with shortages varied with practice structure. Further research is needed to quantitatively assess the impact of drug shortages on patients and evaluate various strategies for managing them.

Original languageEnglish (US)
Pages (from-to)e154-e162
JournalJournal of Oncology Practice
Volume11
Issue number2
DOIs
StatePublished - Mar 1 2015

Fingerprint

Pharmaceutical Preparations
Odds Ratio
Veterans
Physicians
Colorectal Neoplasms
Lung Neoplasms
Group Practice
Leucovorin
Health Maintenance Organizations
Oncologists
Etoposide
Vitamin B 12
Fluorouracil
Dexamethasone
Neoplasms
Logistic Models
Demography
Outcome Assessment (Health Care)
Injections
Research

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Health Policy

Cite this

Kehl, K. L., Gray, S. W., Kim, B., Kahn, K. L., Haggstrom, D., Roudier, M., & Keating, N. L. (2015). Oncologists' experiences with drug shortages. Journal of Oncology Practice, 11(2), e154-e162. https://doi.org/10.1200/JOP.2014.000380

Oncologists' experiences with drug shortages. / Kehl, Kenneth L.; Gray, Stacy W.; Kim, Benjamin; Kahn, Katherine L.; Haggstrom, David; Roudier, Maryse; Keating, Nancy L.

In: Journal of Oncology Practice, Vol. 11, No. 2, 01.03.2015, p. e154-e162.

Research output: Contribution to journalArticle

Kehl, KL, Gray, SW, Kim, B, Kahn, KL, Haggstrom, D, Roudier, M & Keating, NL 2015, 'Oncologists' experiences with drug shortages', Journal of Oncology Practice, vol. 11, no. 2, pp. e154-e162. https://doi.org/10.1200/JOP.2014.000380
Kehl KL, Gray SW, Kim B, Kahn KL, Haggstrom D, Roudier M et al. Oncologists' experiences with drug shortages. Journal of Oncology Practice. 2015 Mar 1;11(2):e154-e162. https://doi.org/10.1200/JOP.2014.000380
Kehl, Kenneth L. ; Gray, Stacy W. ; Kim, Benjamin ; Kahn, Katherine L. ; Haggstrom, David ; Roudier, Maryse ; Keating, Nancy L. / Oncologists' experiences with drug shortages. In: Journal of Oncology Practice. 2015 ; Vol. 11, No. 2. pp. e154-e162.
@article{f25a703383ac4e88ba5854edf2c5357d,
title = "Oncologists' experiences with drug shortages",
abstract = "Purpose: There have been numerous reports of shortages of injectable drugs for cancer in the last decade. We assessed physician experiences with drug shortages in a population-based cohort of medical oncologists caring for patients with lung or colorectal cancer. Methods: Wesurveyed medical oncologists caring for patients with lung or colorectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium from 2012 to 2013 (participation rate, 53{\%}). Oncologists reported experiences with shortages of leucovorin, fluorouracil, dexamethasone, cyanocobalamin, paclitaxel, cisplatin, and etoposide in the prior year and whether they had used a less-effective alternative because of a shortage. We used multivariable logistic regression to assess for associationsbetweenphysician or practice characteristics and encountering shortages. Results: Among 330 respondents, 74{\%} reported experiences with a shortage of at least one drug in our survey, and 28{\%} reported using a less-effective alternative because of a shortage. Although physician demographic characteristics did not predict reports of drug shortages, practice characteristics did. Veterans Affairs (VA) oncologists were less likely to report experiencing any shortage than oncologists in single-specialty group practice (odds ratio [OR], 0.4; 95{\%} CI, 0.2 to 0.9). The reported use of a less effective alternative to any drug was also less common among VA oncologists (OR, 0.3; 95{\%} CI, 0.1 to 0.9) and oncologists affiliated with health maintenance organizations (OR, 0.4; 95{\%} CI, 0.2 to 0.9) compared with physicians in single-specialty groups. Conclusion: Most oncologists encountered drug shortages in the year before our survey, but experiences with shortages varied with practice structure. Further research is needed to quantitatively assess the impact of drug shortages on patients and evaluate various strategies for managing them.",
author = "Kehl, {Kenneth L.} and Gray, {Stacy W.} and Benjamin Kim and Kahn, {Katherine L.} and David Haggstrom and Maryse Roudier and Keating, {Nancy L.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1200/JOP.2014.000380",
language = "English (US)",
volume = "11",
pages = "e154--e162",
journal = "Journal of Oncology Practice",
issn = "1554-7477",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Oncologists' experiences with drug shortages

AU - Kehl, Kenneth L.

AU - Gray, Stacy W.

AU - Kim, Benjamin

AU - Kahn, Katherine L.

AU - Haggstrom, David

AU - Roudier, Maryse

AU - Keating, Nancy L.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Purpose: There have been numerous reports of shortages of injectable drugs for cancer in the last decade. We assessed physician experiences with drug shortages in a population-based cohort of medical oncologists caring for patients with lung or colorectal cancer. Methods: Wesurveyed medical oncologists caring for patients with lung or colorectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium from 2012 to 2013 (participation rate, 53%). Oncologists reported experiences with shortages of leucovorin, fluorouracil, dexamethasone, cyanocobalamin, paclitaxel, cisplatin, and etoposide in the prior year and whether they had used a less-effective alternative because of a shortage. We used multivariable logistic regression to assess for associationsbetweenphysician or practice characteristics and encountering shortages. Results: Among 330 respondents, 74% reported experiences with a shortage of at least one drug in our survey, and 28% reported using a less-effective alternative because of a shortage. Although physician demographic characteristics did not predict reports of drug shortages, practice characteristics did. Veterans Affairs (VA) oncologists were less likely to report experiencing any shortage than oncologists in single-specialty group practice (odds ratio [OR], 0.4; 95% CI, 0.2 to 0.9). The reported use of a less effective alternative to any drug was also less common among VA oncologists (OR, 0.3; 95% CI, 0.1 to 0.9) and oncologists affiliated with health maintenance organizations (OR, 0.4; 95% CI, 0.2 to 0.9) compared with physicians in single-specialty groups. Conclusion: Most oncologists encountered drug shortages in the year before our survey, but experiences with shortages varied with practice structure. Further research is needed to quantitatively assess the impact of drug shortages on patients and evaluate various strategies for managing them.

AB - Purpose: There have been numerous reports of shortages of injectable drugs for cancer in the last decade. We assessed physician experiences with drug shortages in a population-based cohort of medical oncologists caring for patients with lung or colorectal cancer. Methods: Wesurveyed medical oncologists caring for patients with lung or colorectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium from 2012 to 2013 (participation rate, 53%). Oncologists reported experiences with shortages of leucovorin, fluorouracil, dexamethasone, cyanocobalamin, paclitaxel, cisplatin, and etoposide in the prior year and whether they had used a less-effective alternative because of a shortage. We used multivariable logistic regression to assess for associationsbetweenphysician or practice characteristics and encountering shortages. Results: Among 330 respondents, 74% reported experiences with a shortage of at least one drug in our survey, and 28% reported using a less-effective alternative because of a shortage. Although physician demographic characteristics did not predict reports of drug shortages, practice characteristics did. Veterans Affairs (VA) oncologists were less likely to report experiencing any shortage than oncologists in single-specialty group practice (odds ratio [OR], 0.4; 95% CI, 0.2 to 0.9). The reported use of a less effective alternative to any drug was also less common among VA oncologists (OR, 0.3; 95% CI, 0.1 to 0.9) and oncologists affiliated with health maintenance organizations (OR, 0.4; 95% CI, 0.2 to 0.9) compared with physicians in single-specialty groups. Conclusion: Most oncologists encountered drug shortages in the year before our survey, but experiences with shortages varied with practice structure. Further research is needed to quantitatively assess the impact of drug shortages on patients and evaluate various strategies for managing them.

UR - http://www.scopus.com/inward/record.url?scp=84925302619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925302619&partnerID=8YFLogxK

U2 - 10.1200/JOP.2014.000380

DO - 10.1200/JOP.2014.000380

M3 - Article

VL - 11

SP - e154-e162

JO - Journal of Oncology Practice

JF - Journal of Oncology Practice

SN - 1554-7477

IS - 2

ER -